Evaluation of the efficacy, tolerability and safety of Chondrogard in patients with osteoarthrosis of the knee and comorbidity


Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

Osteoarthrosis (OA) is one of the most common joint diseases among diseases of the musculoskeletal system. In the population, the prevalence of this disease correlates with age, reaching the maximum (60-70%) over the age of 65 years. According to the epidemiological study, OA with the primary lesion of knee and/or hip affects 13.0% of the population in Russia. Progression of OA leads to a significant deterioration in the quality of life of patients due to persistent pain syndrome, impaired functional state of the joints, and is often the cause of disability, which is an important social and economic problem. It was found that OA refers to diseases with high comorbidity, and most often is combined with arterial hypertension and other cardiovascular diseases (coronary artery disease, atherosclerosis), obesity, diabetes mellitus, chronic kidney disease, chronic lung diseases, and gastrointestinal diseases.

Full Text

Restricted Access

About the authors

E. P Sharapova

FSBIS “Scientific Research Institute of Rheumatology n.a. V.A. Nasonova" RAMS

N. G Kashevarova

FSBIS “Scientific Research Institute of Rheumatology n.a. V.A. Nasonova" RAMS

E. A Taskina

FSBIS “Scientific Research Institute of Rheumatology n.a. V.A. Nasonova" RAMS

S. G Anikin

FSBIS “Scientific Research Institute of Rheumatology n.a. V.A. Nasonova" RAMS

T. A Korotkova

FSBIS “Scientific Research Institute of Rheumatology n.a. V.A. Nasonova" RAMS

L. I Alekseeva

FSBIS “Scientific Research Institute of Rheumatology n.a. V.A. Nasonova" RAMS

Email: dr.alekseeva@gmail.com
MD, Head of the Division of Metabolic Diseases of Bones and Joints with the Center for the Prevention of Osteoporosis of RMH

References

  1. Arden N., Nevit M.C. Osteoarthritis: Epidemiology. Best Practice and Research Clinical Rheumatology. 2006;20(1):3-25.
  2. Галушко Е.А. Медикосоциальная значимость ревматических заболеваний. Дисс. докт. мед. наук. М., 2011.
  3. Sangha O. Epidemiology of rheumatic disease. Rheumatology. 2000;39(2):3-12.
  4. Nguyen U.S., Zhang Y., Zhu Y. Increasing prevalence of knee pain and symptomatic knee osteoarthritis: survey and cohort data. Ann. Intern. Med. 2011;155:725-32.
  5. Feinstein A.R. Pretherapeutic classification of co-morbidity in chronic disease. J. Chronic Disease. 1970;23(7):455-68.
  6. Kraemer H.C. Statistical issues in assessing comorbidity. Stat. Med. 1995;14:721-23.
  7. Van den Akker M., Buntinx F., Roos S., Knottnerus J.A. Comorbidity or multimorbidity: what is in a name? A review of the literature. Eur. J. Gen. Pract. 1996;2(2):65-70.
  8. Neogi T., Zhang Y. Epidemiology of OA. Rheum. Dis. Clin. North. Am. 2013;39(1):1-19.
  9. Lane N.E., Nevit M.C., Hochberg M.C., Hung Y.Y., Palermo L. Progression of radiographic hip osteoarthritis over eight years in a community sample of elderty white women. Arthr. Rheum. 2004;50:1472-86.
  10. Nuesch E., Dieppe P., Reichenbach S., William S., Juni P. Disability and mortality in patients with osteoarthritis. BMJ. 2011;342:d1165.
  11. McAUndon T.E., Bannuru R.R., Sullivan M.C., Arden N.K., Berenbaum F., Bierma-Zeinstra S.M., Hawker G.A., Henrotin Y., Hunter D.J., Kawaguchi H., Kwoh K., Lohmander S., Rannou F., Roos E.M., Underwood M. OARSI guidelines for the nonsurgical management of knee osteoarthritis. Osteoarthritis Cartilage. 2014;22: 363-88.
  12. Diaz V.B., Fuents E.P., Martinez O.E. Chondroitin Sulfate (Overview) in Polymeric Materials. Encyclopedia. 1996;2.
  13. Шостак Н.А. Остеоартроз: актуальные вопросы диагностики и лечения. РМЖ. 2014;4:274
  14. Olivero U., Sorrentino G.P., De-Paolo P., Tranfaglia.E., D'Alessandro A., Carifi S., Porfido F.A., Cerio R., Grasso A.M., Policicchio D. Effects of treatment with matrix on elderly people with chronic articular degeneration. Drugs Exp. Clin. Res. 1991;17:45-51.
  15. Mazierres B., Loyau G., Menkes C.J., Valat J.P., Dreiser R.L., Charlot J., Masounabe-Puyanne A. Chondroitin sulfate in the treatment of gonarthritis and coxarthrosis. Rev. Mal. Osteoartic. 1992;59:466-72.
  16. Singh J.A., Noorbaloochi S., Maxwell L.J. Chondroitin for osteoarthritis (Review). Cochrane Datebase Syst. Rev. 2015.
  17. Eugenio-Sarmiento R.M., Vanapat D.H.D., Salido E.J. The efficacy of chondroitin sulfate in the treatment of knee osteoarthritis: a meta-analysis. Osteoarthritis Cartilage. 1999;7(l):139.
  18. Lebb B.F., Schweitzer H., Montag K., Smolen J.S. A meta-analysis of chondroitin sulfate in the treatment of osteoarthritis. J. Rheum. 2000;27:205-11.
  19. Schneider H. Symptom-Modifying Effect of chondroitin sulfate in Knee Osteoarthritis: а metaanalysis Placebo-Controlled Trials Performed with Structum. Open Rheumatol. J. 2012:6:183-89.
  20. Conte A., De Bernardi M., Palmieri L., Lualdi P, Mautone G., Ronca G. Metabolic fate of exogenous chondroitin-sulfate in man. ArzeimForch/Drug Res. 1991;41:768- 72.
  21. Palmieri L., Conte A., Giovannini L., Lualdi P., Ronca G. Metabolic fate of exogenous chondroitinsulfate in the experimental animal. Arzeim-Forch/ Drug Res. 1990;40:319-23.
  22. Пешехонова Л.К., Пешехонов Д.В. Современные тенденции патогенетической терапии остеоартроза. РМЖ. 2012;30:1500.
  23. Алексеева Л.И., Аникин С.Г., Зайцева Е.М., Кашеварова Н.Г., Короткова Т.А., Шарапова Е.П., Чичасова Н.В., Имаметдинова Г.Р., Бадокин Н.В., Колова С.А. Исследование эффективности, переносимости и безопасности препарата Хондрогард у пациентов с остеоартрозом. РМЖ. 2013;32:1624.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2017 Bionika Media

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies